Blood–brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Comprehensive Overview
Published in Nature Communications in 2018, this Canadian phase I trial set out to test whether a noninvasive ultrasound technique could safely and temporarily breach the blood-brain barrier (BBB), the protective lining that normally blocks most drugs from reaching brain tissue, in people with Alzheimer's disease, as a first step toward one day delivering therapies directly to the diseased brain. Researchers at Sunnybrook Health Sciences Centre in Toronto screened 21 candidates and enrolled five patients (three men, two women, average age 66) with mild-to-moderate Alzheimer's disease confirmed by a specialized brain scan showing abnormal buildup of the sticky protein beta-amyloid. Using MR-guided focused ultrasound (MRgFUS), a helmet-like device that aims sound waves at a precise brain target while a patient lies in an MRI scanner, combined with an intravenous injection of tiny gas-filled microbubbles, the team briefly opened the barrier in a small region of the frontal lobe, repeating the procedure about one month later in a larger volume. Patients were monitored with brain scans and cognitive testing for two months afterward. As expected from earlier animal research, the procedure successfully and safely opened the barrier in every patient, with the opening fully closing again within 24 hours.
Outcomes and Implications
The single most important finding is that this fragile, elderly population tolerated repeated, targeted breaching of the blood-brain barrier with no serious complications: no deaths, bleeding, brain swelling, or lasting neurological problems, and no meaningful decline in memory or daily functioning three months later. A few minor wrinkles emerged along the way: one patient temporarily scored worse on a behavioral symptoms questionnaire, another developed headaches later traced to an outdated eyeglass prescription, and two patients showed small spots on imaging suggestive of tiny bleeds that vanished within a day rather than lingering as true microbleeds typically do. A closer look at amyloid buildup on PET scans, however, found no clear group-wide reduction after the barrier was opened, meaning opening it alone did not clear plaques in this short study. This matters because decades of Alzheimer's drug development have stalled partly because promising compounds, including large antibodies, cannot reach the brain in sufficient concentration past the blood-brain barrier, and earlier delivery methods have failed on safety or precision grounds. A reversible, image-guided ultrasound approach that closes within 24 hours offers a notably safer alternative, though the small sample of five patients, several with early-onset disease, limits how broadly these findings apply. The authors conclude that larger trials should extend this technique to memory-critical regions such as the hippocampus, enroll patients earlier in the disease course, and pair barrier opening with an actual drug to determine whether the strategy can meaningfully benefit patients.